- Home
- RPRX vs PEN Comparison
RPRX vs PEN Comparison
Compare RPRX & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | PEN |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 13.2B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RPRX | PEN |
|---|---|---|
| Price | $46.19 | $335.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 17 |
| Target Price | $47.75 | ★ $357.33 |
| AVG Volume (30 Days) | ★ 3.1M | 576.3K |
| Earning Date | 05-06-2026 | 05-26-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | N/A | ★ 1155.56 |
| EPS | 1.78 | ★ 4.52 |
| Revenue | ★ $2,378,193,000.00 | $1,403,665,000.00 |
| Revenue This Year | $38.30 | $14.20 |
| Revenue Next Year | $4.80 | $13.60 |
| P/E Ratio | ★ $26.22 | $74.35 |
| Revenue Growth | 5.06 | ★ 17.50 |
| 52 Week Low | $29.66 | $221.26 |
| 52 Week High | $47.86 | $362.41 |
Technical Indicators
Market Signals| Indicator | RPRX | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.46 | 41.55 |
| Support Level | $35.32 | $302.19 |
| Resistance Level | $46.14 | $344.07 |
| Average True Range (ATR) | 0.90 | 2.37 |
| MACD | -0.19 | -0.97 |
| Stochastic Oscillator | 37.86 | 11.30 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.